IL2 and lymphoma: Whether the prolonged IL-2 may have had any role in the patient’s subsequent lymphoma relapse is speculative; we would note that the patient’s risk of lymphoma relapse was quite high on clinical grounds, in view of his aggressive initial presentation and, in particular, his short disease-free interval after initial therapy.